GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Novacyt SA (XPAR:ALNOV) » Definitions » Debt-to-Revenue

Novacyt (XPAR:ALNOV) Debt-to-Revenue : 0.06 (As of Jun. 2023)


View and export this data going back to 2012. Start your Free Trial

What is Novacyt Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Novacyt's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was €0.20 Mil. Novacyt's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was €0.26 Mil. Novacyt's annualized Revenue for the quarter that ended in Jun. 2023 was €7.78 Mil. Novacyt's annualized Debt-to-Revenue for the quarter that ended in Jun. 2023 was 0.06.


Novacyt Debt-to-Revenue Historical Data

The historical data trend for Novacyt's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novacyt Debt-to-Revenue Chart

Novacyt Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.39 0.82 0.01 0.02 0.04

Novacyt Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.02 0.05 0.10 0.06

Competitive Comparison of Novacyt's Debt-to-Revenue

For the Medical Devices subindustry, Novacyt's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novacyt's Debt-to-Revenue Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Novacyt's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Novacyt's Debt-to-Revenue falls into.



Novacyt Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Novacyt's Debt-to-Revenue for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.7 + 0.302) / 24.192
=0.04

Novacyt's annualized Debt-to-Revenue for the quarter that ended in Jun. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.198 + 0.255) / 7.782
=0.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is two times the quarterly (Jun. 2023) Revenue data.


Novacyt Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Novacyt's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Novacyt (XPAR:ALNOV) Business Description

Traded in Other Exchanges
Address
13, Avenue Morane Saulnier, Velizy-Villacoublay, FRA, 78140
Novacyt SA is engaged in developing and selling diagnostic products for cancer and infectious diseases. The company operates its business through the following business segments. Primerdesign is the designer, manufacturer, and marketer of molecular 'real-time' qPCR testing devices and reagents in the areas of infectious diseases based in Southampton, UK: IT-IS International segment develops PCR devices for the life sciences and food testing industry and Corporate segment.

Novacyt (XPAR:ALNOV) Headlines

No Headlines